(PDF) Reply To: Need for Improvements in Reported

Reply To: Need for Improvements in Reported Cost-Effectiveness of Adalimumab in Rheumatoid Arthritis

Zeitschrift fur Rheumatologie - Germany

doi 10.1007/s00393-016-0256-2

Full Text

Abstract

Available in full text

Categories

Date

January 13, 2017

Authors

Publisher

Springer Science and Business Media LLC

Related search

Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany

Value in Health

Occupational Health

English

Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain

ClinicoEconomics and Outcomes Research

English

Pms47 - Cost-Effectiveness of Tofacitinib Compared With Adalimumab in the Treatment of Moderate to Severe Rheumatoid Arthritis in Iran

Value in Health

Occupational Health

English

Cost-Effectiveness of Abatacept Compared to Adalimumab in Italy Based on a Head-To-Head Outcomes Study in Rheumatoid Arthritis

Value in Health

Occupational Health

English

Cost Effectiveness of TNF-αInhibitors in Rheumatoid Arthritis

International Journal of Inflammation

English

The Cost-Effectiveness of Alternative Treatment Sequences in Rheumatoid Arthritis

Value in Health

Occupational Health

English

Adalimumab in the Treatment of Early Rheumatoid Arthritis

Nauchno-Prakticheskaya Revmatologiya

English

Pms51 - Cost-Effectiveness of Tofacitinib-Containing Sequences for Rheumatoid Arthritis Patients in Spain

Value in Health

Occupational Health

English

Mean Cost Per Number Needed to Treat of Baricitinib Versus Adalimumab in the Treatment of Rheumatoid Arthritis in Italy

Global and Regional Health Technology Assessment

English